Home
About Us
Group Introduction
Founder Introduction
Global Cooperation
Nanolattix Biotechnology
Company Profile
Development History
Research Layout
Nanolattix Health
Extraction Platform
Cosmetics
Machine
Food Brand
Disinfection
Oem/Odm
News
Company News
Industry News
Contact Us
简体中文
English
Release time:
2025-01-10
Nanolattix T320 Cancer Drug Successfully Receives U.S. FDA Clinical Approval
Tag:
Previous Page
None
2024.11
Next Page
Previous Page:
Next page:
recommend News
Nanolattix Announces Three Studies Selected for the ASCO 2026 Annual Meeting, Highlighting International Recognition of Innovative RDC+ADC Paradigm
2026-05-25
Clinical Trial Recruitment for T320, a Novel TF-Targeting Anti-Cancer Drug
2025-07-09
Nanolattix’s T320-ADC Multi-Center Clinical Trials Initiated, Accelerating Development of Advanced Solid Tumor Therapies
Media Focus | Tonacea: ADC Accelerates Iteration, RDC Gains Momentum – Trends at ASCO 2026 and Nanolattix‘s Strategic Logic
2026-06-02
Media Focus | Tonacea: Under the Dual-Mode Narrative, Nanolattix Launches a Synergistic Offensive
2026-04-27
Share
